The collaboration between Rhythm Pharmaceuticals and Genpharm will expand the availability of IMCIVREE, an obesity treatment drug, to patients in Gulf Cooperation Council countries. This partnership has the potential to increase Rhythm Pharmaceuticals' market presence and revenue in the region, leading to a positive short-term impact on the company's stock price.